Introduction
Since covid19 pandemic, safe and effective vaccination against it became so important. Up to now, more than 50 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed in clinical trials. Chadox1 ncov-19 (AZD1222) is one of them which has been used in national vaccination programs against the disease in many countries 1. Viral infection after covid 19 vaccination have been reported. Furer et al, has reported six cases of herpes zoster following BNT162b2 mRNA Covid-19 vaccination 2.
Herpes virus reactivation has been reported following trivalent influenza, hepatitis A, and rabies vaccines, suggesting vaccine-modulated immunomodulation3. To our knowledge there were no case reports of herpes simplex infections or herpes like skin lesions in the chadox1 ncov-19 (azd1222) vaccine clinical trials4, but some cases have been reported in the UK spontaneous reports received between April 1st to April 14th 2021 for COVID-19 vaccine Oxford University/AstraZeneca.
In this study we are going to report a Herpes simplex virus (HSV) reactivation following chadox1 ncov-19 (AZD1222) vaccination.